Included support
- ✓Hospital matching
- ✓Record review
- ✓Care coordination
- ✓Travel support
- ✓Interpretation support

CAR-T cell therapy may be considered in children with relapsed/refractory B-cell acute lymphoblastic leukemia or persistent MRD positivity, with CD19/CD22 as common targets. The decision depends on antigen expression, previous treatment and relapse risk, whether bridging therapy is needed, organ fun
24–72h
响应时间
Approx. $5,400
起价
Varies by procedure
治疗周期
1+ options
合作医院
经过病例审核后,我们将根据治疗适配度推荐医院和城市。
Treatment brief
Review the treatment pathway, hospital options, estimated costs, and practical preparation in one place. The final recommendation is based on your records and a specialist review.
Hospital matching
Compare suitable hospitals and departments before you commit to travel.
Record review
Our team helps organise your medical records and first-step case information.
Care coordination
Support around scheduling, practical preparation, and treatment planning.
Travel support
Help with the practical side of arriving, attending appointments, and recovery.
Your care pathway
让我们为您协调治疗旅程。
Step 1
Share your diagnosis, records, and goals so the team can assess the case.
Step 2
Receive suitable options based on condition, budget, timeline, and city preference.
Step 3
Get support with invitation materials and practical travel planning.
Step 4
The team supports your arrival, appointments, and care coordination in China.
Step 5
Continue with aftercare planning and remote follow-up after returning home.
CAR-T is based on the patient's own or, if applicable, donor T cells, which are genetically modified in vitro to obtain a chimeric antigen receptor, commonly targeting CD19 or CD22. Usually, after collection and preparation are completed, a short course of lymphodepleting preconditioning is given, and then the expanded CAR-T cells are returned intravenously; during hospitalization, body temperature, blood pressure, neurological signs, and laboratory indicators are closely monitored, and supportive treatment is given. The overall goal is to maintain organ stability while controlling the lesions. The above is general health information, not medical advice; the specifics are subject to specialist assessment and hospital protocols.
Considering screening and collection, cell preparation, hospitalization, and post-discharge follow-up, it is recommended to stay in China for approximately 5–8 weeks; subject to the actual process and assessment.
Recovery snapshot
Recovery time and follow-up depend on the procedure and your clinical situation. Your hospital team confirms the schedule before treatment, while our coordinators help organise the practical details around it.
Tell us about your Pediatric Leukemia case and we will help match you with the right hospital, specialist, and travel pathway.
Suitability is confirmed after a qualified clinician reviews your diagnosis and records.
Risks, alternatives, expected outcomes, and limitations must be explained by the treating hospital.
Appointment and treatment timing depends on clinical review, hospital capacity, visa readiness, and scheduling.
Prices are case-specific. A written estimate should be confirmed by the hospital before travel.
Medical Tourism China provides coordination and general information, not medical advice. Final diagnosis, eligibility, treatment decisions, risks, fees, and follow-up remain with the licensed treating hospital.
来源:医院及医疗协调资料;更新时间:2026年7月。治疗适用性、费用和时间须以医院审核结果为准。